The global healthcare landscape is changing at an unprecedented rate, and the clinical lab is in the epicenter of that change. Lab’s potential impact doesn’t end when we release a result; rather, that’s where it begins!

Monday, October 26, 2020

Please note that sessions times listed are in Central Time

9:00 AM  ̶  9:30 AM


Welcome: CL2.0 After Drinking From the Firehose?

It’s been wild ride! Extraordinary times call for extraordinary discourse. The Project Santa Fe Foundation Board of Directors welcomes you to the Clinical Lab 2.0 conversation.

David Nash, MD
David N. Sundwall, MD

9:30 AM  ̶  10:30 AM


Keynotes: Population Health and Public Health During a Pandemic

David B. Nash, MD, MBA, Founding Dean Emeritus, Jefferson College of Population Health, Philadelphia, PA

David N. Sundwall, MD, Professor Emeritus, Public Health, Department of Family and Preventive Medicine, University of Utah School of Medicine, Chief Medical Officer, Rocky Mountain Care, Salt Lake City, UT


Dr. David Nash, founding Dean Emeritus and Professor of Health Policy at the Jefferson College of Population Health, and Dr. David Sundwall, Professor Emeritus of Public Health at the University of Utah School of Medicine, will lead a discussion about population health and public health during and after the pandemic and what that means for a Clinical Lab 2.0 model.

Mark D. Dixon, R.Ph., MHA, FACHE

10:45 AM  ̶  11:45 AM


Stakeholder Panel: There’s No Looking Back: How COVID-19 Changed the Healthcare Ecosystem

Facilitator: Mark D. Dixon, R.Ph., MHA, FACHE, President, The Mark Dixon Group, LLC, Edina, MN

Panelists:

  • David W. Johnson, Chief Executive Officer, 4sight Health, Chicago, IL
  • David B. Nash, MD, MBA, Founding Dean Emeritus, Jefferson College of Population Health, Philadelphia, PA
  • David N. Sundwall, MD, Professor Emeritus, Public Health, Department of Family and Preventive Medicine, University of Utah School of Medicine, Chief Medical Officer, Rocky Mountain Care, Salt Lake City, UT
  • William P. Santulli, Chief Operating Officer, Advocate Aurora Health, Downers Grove, IL

Dr. Nash and Dr. Sundwall will then be joined by David Johnson, Bill Santulli, and Mark Dixon for in-depth dialogue about COVID-19’s impact on the healthcare ecosystem and the shifting priorities of the clinical laboratory’s stakeholders.

David W. Johnson
David W. Johnson
David Nash, MD
David N. Sundwall, MD
Bill P. Santulli
Mark Fung, MD
Mark Fung, MD

12:00 PM  ̶  12:30 PM


The CL2.0 Model: Creating New Norms to Solve New Problems

Mark Fung, MD, PhD, Professor and Vice Chair for Population Health, Department of Pathology and Laboratory Medicine, The Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT


Dr. Mark Fung will propose a CL2.0 model for COVID-19 response, creating new norms for solving the new problems facing out stakeholders and our communities.

Mark D. Dixon, R.Ph., MHA, FACHE

12:30 PM  ̶  1:15 PM


The CL2.0 Model – Stakeholders React

Facilitator: Mark D. Dixon, R.Ph., MHA, FACHE, President, The Mark Dixon Group, LLC, Edina, MN

Panelists:

  • David W. Johnson, Chief Executive Officer, 4sight Health, Chicago, IL
  • David B. Nash, MD, MBA, Founding Dean Emeritus, Jefferson College of Population Health, Philadelphia, PA
  • David N. Sundwall, MD, Professor Emeritus, Public Health, Department of Family and Preventive Medicine, University of Utah School of Medicine, Chief Medical Officer, Rocky Mountain Care, Salt Lake City, UT
  • William P. Santulli, Chief Operating Officer, Advocate Aurora Health, Downers Grove, IL

Our distinguished stakeholder panel will provide real-time commentary and input on the proposed CL2.0 for COVID -19 Model.

Panelists:

David W. Johnson
David W. Johnson
David Nash, MD
David N. Sundwall, MD
Bill P. Santulli

1:15 PM  ̶  1:30 PM


CL2.0 What’s Next?

CL2.0 is more than COVID. Learn more about Project Santa Fe Foundation initiatives and opportunities for involvement

Tuesday, October 27, 2020

Karen Kaul, MD, PhD
Karen Kaul, MD, PhD
E. Blair Holladay, PhD, MASCP, SCT(ASCP)CM

Please note that sessions times listed are in Central Time

9:00 AM  ̶  9:20 AM


CL2.0 Call to Action!

Karen Kaul, MD, PhD, Chair of the Department of Pathology and Laboratory Medicine, NorthShore University HealthSystem, Evanston, IL

E. Blair Holladay, PhD, MASCP, SCT(ASCP)CM , CEO, American Society of Clinical Pathology, Chicago, IL


Dr. Karen Kaul and Dr. Blair Holladay call to action our industry’s professional societies, critical players to further the CL2.0 movement.

Richard Zarbo, MD, DMD
Aya Haghamad, PharmD
Samuel B. Reichberg, M.D., Ph.D, FCAP

9:20 AM  ̶  10:00 AM


CL2.0 COVID-19 Model in Action – Case Studies from the Front Lines

Richard Zarbo, MD, DMD, SR. VP and Chair, Pathology and Laboratory Medicine, Henry Ford Health System, Detroit, MI

Aya Haghamad, PharmD, Clinical Solutions Specialist, Northwell Health, New Hyde Park, NY

Samuel Reichberg, MD, Ph.D., Associate Medical Director, Northwell Health, New Hyde Park, NY


Members of Project Santa Fe Foundation will walk you through CL2.0 COVID-19 model case studies demonstrated within their respective institutions.

Dr. Donna Wolk serves as the Division Director for the of Molecular and Microbial Diagnostics and Development at Geisinger Health.
Donna Wolk, MHA, Ph.D., D(ABMM)

10:15 AM  ̶  11:15 AM


CL2.0 COVID-19 Model in Action – Case Study from the Front Lines

Donna Wolk, MHA, Ph.D., D(ABMM), Division Director, Molecular and Microbial Diagnostics and Development, Geisinger Health, Danville, PA


Members of Project Santa Fe Foundation will walk you through CL2.0 COVID-19 model case studies demonstrated within their respective institutions.

Beth Bailey
Beth Bailey

11:15 AM  ̶  11:45 AM


CL2.0 Model: CROWDSOURCE! – Add to the Conversation

Beth Bailey, Project Santa Fe Foundation, Faculty
Director of Strategic Development and Communications, TriCore Reference Laboratories, Albuquerque, NM

What do you think? CL2.0 is a movement, requiring engagements across the industry. In this session, we will open the floor to the laboratory community, industry partners and policymakers to add to the proposed CL2.0 model, maximizing our collective impact and amplifying the CL2.0 movement.

Curt Hanson, MD
Curt Hanson, MD

12:00 PM  ̶  1:00 PM


PSFF Board of Directors: Are We There Yet? What else should be done and what do we need to get there?

Recognizing the magnitude of what we have accomplished, join the Project Santa Fe Foundation Board of Directors in a discussion about the work ahead, what is standing the way, and how we might remove these obstacles.

Khosrow Shotorbani, MBA, MT (ASCP)
James Crawford, MD, PhD
Myra Wilkerson, MD
Richard Zarbo, MD, DMD
Karen Kaul, MD, PhD
Karen Kaul, MD, PhD
Michael J. Crossey, MD, PhD
Mark Fung, MD
Mark Fung, MD
Sterling T. Bennett, MD, MS
Khosrow Shotorbani, MBA, MT (ASCP)

1:00 PM  ̶  1:30 PM


The Future World Class Clinical Lab

Khosrow Shotorbani, MBA, MT (ASCP) will tie together the two-day conversation, offering Project Santa Fe’s vision for the future where clinical lab partners with public health to reshape the way healthcare is delivered.